© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Head & Neck Cancers
South Carolina Oncology Practice Continues Cautious Operation Amidst the COVID-19 Pandemic
March 23, 2020
In an interview with Targeted Oncology, Kashyap Patel, MD, discussed the COVID-19 pandemic and the implementation of new precautions in his practice as the number of COVID-19 infected persons rises in the state.
Benefit of PARP Inhibitors May Extend to Certain Tumors With IDH Mutations
March 21, 2020
Patients harboring IDH1/2 muta­tions may receive benefit by the use of PARP inhibitors, with investigators initi­ating clinical trials in patients across multiple different tumor types to determine the efficacy of this strategy.
Pembrolizumab Monotherapy Elicits Responses in Patients With Advanced Rare Cancers
March 20, 2020
Treatment with pembrolizumab demonstrated antitumor activity along with tolerable toxicity in patients with 4 different rare and hard-to-treat malignancies, according to results from a phase II study led by The University of Texas MD Anderson Cancer Center researchers and published in the Journal for ImmunoTherapy of Cancer.
Bevacizumab Biosimilar Under Review by FDA
March 09, 2020
The FDA has accepted a Biologics License Application for MYL-1402O, a proposed biosimilar to bevacizumab, according to a press release from co-developers Biocon and Mylan. The BLA is seeking approval for the biosimilar as a treatment for multiple types of cancer and the FDA has set an action date goal of December 27, 2020, for a decision on the BLA.
Novel Coronavirus Impedes Travel Among Oncologists, But They Remain Undaunted
March 07, 2020
As the new coronavirus disease 2019 creates problems internationally, health-wise and economically, it is also becoming a cause for concern throughout the oncology community.
A Look Back at FDA News from February 2020
March 04, 2020
In February 2020, the FDA gave indications to multiple therapies meant for treatment of solid tumor and hematologic malignancies. FDA action included 10 Priority Reviews, 2 Breakthrough Therapy designations, and 2 Fast Track designations.
ACCC Creates Resources for Multidisciplinary Practices to Prepare for Growing Geriatric Cancer Population
February 25, 2020
To help clinicians cope with an increasing number of geriatric patients with cancer, the Association of Community Cancer Centers is addressing this problem with a 2-pronged approach that focuses on the delivery of care and diagnostic assessment.
FDA Grants Fast Track Designation to NBTXR3 in Locally Advanced Head and Neck Cancers
February 11, 2020
An FDA Fast Track Designation was granted to the first-in-class radioenhancer NBTXR3 with or without cetuximab for the treatment of patients with locally advanced head and neck squamous cell cancer who are not eligible for platinum-based chemotherapy, according to a press release from Nanobiotix.
Lenvatinib/Pembrolizumab Shows Promising Antitumor Activity and Safety in Select Solid Tumors
January 30, 2020
In a phase II trial, the combination of lenvantinib and pembrolizumab demonstrated a manageable safety profile and encouraging antitumor activity in patients with selected advanced solid tumors. The decision to combine the agents was based on preclinical data, which suggested that VEGF and FGF signaling may enhance the therapeutic efficacy of lenvatinib.
First Randomized Clinical Trial Evaluating Geriatric Assessment Reveals High Satisfaction With Communication About Aging-Related Concerns
January 18, 2020
Integrating a geriatric assessment into the care of older adults who are receiving cancer treatment in communi­ty oncology practices improves patient and caregiver satisfaction and encourages commu­nication about aging-related concerns, accord­ing to results of a clinical trial that enrolled 541 patients with advanced cancer.